View
216
Download
1
Tags:
Embed Size (px)
Citation preview
Leprosy (Hansen’s Disease)
Amanda LeeBIOL 402
Leprosy is caused by Mycobacterium leprae
Scollard, DM et al. 2006. “The continuing challenges of leprosy.” Clinical microbiology reviews 19, no. 2: 338-81.
Discovered by Gerhard Armauer Hansen in 1873
Global Project on the History of Leprosyhttp://www.leprosyhistory.org/graphics/gallery/hansen.jpg
Bacteria Resides in Cooler Parts of the Body
http://www.nlm.nih.gov
Skin Peripheral Nerves
Symptoms & Diagnosis: (1) Skin Lesions
Worobec, Sophie M. 2009. “Treatment of leprosy/Hansen's disease in the early 21st century.” Dermatologic therapy 22,
no. 6: 518-37.
Global Project on the History of Leprosyhttp://www.leprosyhistory.org/graphics/gallery/mleprae.jpg
Symptoms & Diagnosis: (2) Skin Smear Tests
Ziehl Neelsen Carbol Fuchsin Stain (ZNCF)
Transmission
Nasal/oral Droplets
Dermal Inoculations
Immunocompromised individuals are more
susceptible to disease
Mechanism of Nerve Damage
Scollard, DM et al. 2006. “The continuing challenges of leprosy.” Clinical microbiology reviews 19, no. 2: 338-81.
1.Entry Through Blood Vessels
2. Inflammatory Response
3. Demyelination
Sensory Loss
Paralysis
Deformities
Outcomes of Nerve Damage
Leprosy: eMedicine Infectious Diseaseshttp://emedicine.medscape.com/article/220455-overview
International Federation of Anti-Leprosy Associations (ILEP)http://www.ilep.org.uk/en/
Sensory Loss Can Lead to Secondary Infections and Severe Deformities
1941: Discovery of Dapsone
Targets dihydropteroate synthase (DHPS)
Inhibits nucleic acid synthesis
1964: Dapsone Resistance from Missense Mutations in DHPS
Matsuoka, Masanori M. 2010. “Drug Resistance in Leprosy.” Japanese journal of infectious diseases 63, no. 1: 1-7.
1960’s: Rifampicin and Clofazimine Discovered
Rifampicin (Rifampin): Inhibit RNA synthesis
Clofazimine: Anti-inflammatory
1981: WHO Proposes Multi-Drug Therapy (MDT) Combination of DAPSONE,
RIFAMPICIN, and CLOFAZIMINE
+ +
The Nippon Foundation http://www.nippon-foundation.or.jp/eng/
1995: WHO Distributes MDT Drugs for Free to Worldwide Patients
1999: Global Alliance to Eliminate Leprosy As a Public Health Problem
Obstacles to Eliminating Leprosy in Endemic Countries
World Health Organization. 2001. “Leprosy: Learning from Success.” WHO Publications on Leprosy.
STIGMA
Overcoming Stigma
Mass Media
Integrated Primary Health Services
Education & Training
Worobec, Sophie M. 2009. “Treatment of leprosy/Hansen's disease in the early 21st century.” Dermatologic therapy 22, no. 6: 518-37.
References1. Leprosy Today. “Leprosy: The Disease.” World Health Organization.
http://www.who.int/lep/leprosy/en/index.html (accessed February 25 2010).
2. Matsuoka, Masanori M. 2010. “Drug Resistance in Leprosy.” Japanese journal of infectious diseases 63, no. 1: 1-7. http://www.nih.go.jp.libproxy.lib.unc.edu (accessed February 25, 2010).
3. National Hansen’s Disease (Leprosy) Program. “Hansen’s Disease (Leprosy) Facts.” U.S. Department of Health and Human Services. http://www.hrsa.gov/hansens/ Accessed February 25 2010.
4. Scollard, DM, LB Adams, TP Gillis, JL Krahenbuhl , RW Truman, and DL Williams. 2006. “The continuing challenges of leprosy.” Clinical microbiology reviews 19, no. 2: 338-81. http://www.ncbi.nlm.nih.gov.libproxy.lib.unc.edu (accessed February 25, 2010).
5. Worobec, Sophie M. 2009. “Treatment of leprosy/Hansen's disease in the early 21st century.” Dermatologic therapy 22, no. 6: 518-37. http://www3.interscience.wiley.com.libproxy.lib.unc.edu (accessed February 25, 2010.